FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
19 letters match. Newest first.
-
DrugsGreen Vitality dba Gr33n
FDA warned Green Vitality dba Gr33n that its Jimerito Honey Eye Drops are an unapproved new drug sold with disease-treatment claims.
High risk -
DrugsMy Holistic Honey c/o Shenzhen Qanhai Wanb Express Supply Chain Co., LTD
FDA warned My Holistic Honey that its honey eye drops are an unapproved new drug sold with drug claims.
High risk -
DrugsHomeopathic Educational Services dba Homeopathic Family Medicine
FDA says Homeopathic Family Medicine sells unapproved Cineraria Maritima Eye Drops for cataracts online.
High risk -
DrugsMel Honey US
FDA warned Mel Honey US that its Jimerito (Melipona) Honey eye drops are an unapproved new drug.
High risk -
DrugsSupply Center USA
Supply Center USA offered unapproved Similasan and Boiron eye drug products for sale online.
High risk -
DrugsTrew Balance
FDA warned Trew Balance that its Trew Vision CBD Eye Drops are an unapproved new drug sold with disease-treatment claims.
High risk -
DrugsLife Enthusiast Co-op
FDA tells Life Enthusiast Co-op its three eye products sold online are unapproved new drugs.
High risk -
DrugsOasis Medical, Inc.
FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.
High risk -
DrugsScope Health Inc
FDA says Scope Health sold unapproved OTC eye drugs online and misbranded several products.
High risk -
DrugsEyeTech One, LLC
FDA warns EyeTech One that its EYELIVIO lubricant eye ointment is an unapproved new drug and misbranded.
Medium -
DrugsOSRX, Inc.
OSRX, a Montana compounding facility, made sterile ophthalmic drugs under insanitary conditions with quality and labeling failures.
High risk -
DrugsRegenerative Processing Plant, LLC
FDA warns Regenerative Processing Plant over unapproved, misbranded Regener-Eyes eye drops and serious sterile manufacturing violations.
High risk -
DrugsVelocity Pharma LLC
Velocity Pharma distributed eye drop drugs made by contract manufacturers with serious manufacturing and sanitation violations.
High risk -
DrugsOptikem International Inc.
FDA warns Optikem International after inspection found inadequate aseptic controls for sterile ophthalmic drugs, including contamination and validation failures.
High risk -
DrugsAmazon.com, Inc.
FDA warned Amazon for selling seven unapproved eye drug products on Amazon.com.
High risk -
DrugsSimilasan AG
Similasan AG's ophthalmic drugs are unapproved new drugs and violate CGMP (manufacturing quality rules), FDA says.
High risk -
DrugsK.C. Pharmaceuticals Inc.
FDA warned K.C. Pharmaceuticals after inspections found manufacturing rule violations in sterile ophthalmic drugs, including inadequate contamination controls and cleaning validation.
High risk -
DrugsPharmedica USA, LLC
FDA found Pharmedica made ophthalmic and nasal drugs under insanitary conditions without required sterile controls.
High risk -
DrugsSterling Pharmaceutical Services, LLC
Sterling Pharmaceutical Services, LLC made sterile ophthalmic drugs with manufacturing violations and marketed unapproved new drugs.
High risk